(Q24247400)

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

How do the currently used prophylactic agents work in migraine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Patient numbers needed in prophylactic migraine trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

Feverfew as a preventive treatment for migraine: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

The Essential Oil ofTanacetum parthenium (L.) Schultz-Bip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Melatonin in feverfew and other medicinal plants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Towards a definition of migraine headache

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Randomised double-blind placebo-controlled trial of feverfew in migraine prevention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Compositae dermatitis in South Australia: contact dermatitis from Chrysanthemum parthenium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Prostaglandin synthetase inhibitors in feverfew

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021

Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in-vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002286.PUB2

7 January 2021